Science & Enterprise subscription

Follow us on Twitter

  • A clinical trial is underway assessing a drug approved for a rare inherited disease as a treatment for people hospi… https://t.co/Jyaa0PlA4A
    about 3 hours ago
  • New post on Science and Enterprise: Trial Testing Rare Disease Drug for Covid-19 Pneumonia https://t.co/2hAsoiN16x #Science #Business
    about 3 hours ago
  • Discoveries in a university lab that enable detection of Covid-19 infections from a person's breath are being licen… https://t.co/DgmvR2EcTr
    about 19 hours ago
  • New post on Science and Enterprise: Breath Analysis Sensor Licensed to Detect Covid-19 https://t.co/IZh1x1rqfo #Science #Business
    about 19 hours ago
  • Seven new vaccine projects got underway last week, raising the total to 164, with six more vaccines reaching clinic… https://t.co/VvvPn7PGgu
    about 1 day ago

Please share Science & Enterprise

Covid-19 Vaccines, Therapies – 27 July 2020

Covid-19 vaccine and therapy tracker

BioRender Covid-19 vaccine and therapy tracker. (BioRender.com)

27 July 2020. A regular Monday feature each week on Science & Enterprise is an update on Covid-19 therapies and vaccines in development. The report is provided by BioRender, in Toronto, Ontario, a company offering illustration and graphics tools for life sciences, biotechnology, and other disciplines.

This week’s chart shows since last Monday more new activity for therapies than vaccines, with 15 new Covid-19 therapies joining the array of treatments in development. Of the 337 total therapies, 252 of these treatments are in clinical trials, a gain of 16 since last Monday. Also since last Monday, one more new candidate joined the Covid-19 vaccine collection raising the total to 156. Of that number, 34 vaccine candidates are in clinical trials, a gain of three since last week.

In addition to the summary dashboard shown above, the BioRender Covid-19 vaccine and therapy page provides details of the vaccines and therapies, as well as an activity feed showing news updates on these drugs.

A story in this morning’s New York Times reminds us that not all antibodies produced by Covid-19 vaccines, or the tests that detect them, are alike. The most potent neutralizing antibodies are those that block proteins on the SARS-CoV-2 coronavirus spike from infecting cells, while other antibodies bind to the virus without neutralizing it. Early-stage clinical trials look primarily for safety issues with vaccines, but also for the candidate’s ability to produce an immune response. As vaccines progress into later stage trials, we will watch for candidates’ performance in producing these more potent antibodies.

More from Science & Enterprise:

*     *     *

2 comments to Covid-19 Vaccines, Therapies – 27 July 2020